Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Retained Earnings (2021 - 2025)

Bioventus (BVS) has disclosed Retained Earnings for 5 consecutive years, with -$334.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 6.36% year-over-year to -$334.9 million, compared with a TTM value of -$334.9 million through Dec 2025, up 6.36%, and an annual FY2025 reading of -$334.9 million, up 6.36% over the prior year.
  • Retained Earnings was -$334.9 million for Q4 2025 at Bioventus, down from -$1.8 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $655000.0 in Q3 2023 and bottomed at -$360.3 million in Q1 2025.
  • Average Retained Earnings over 5 years is -$126.0 million, with a median of -$17.9 million recorded in 2022.
  • The sharpest move saw Retained Earnings surged 102.61% in 2023, then tumbled 110960.92% in 2025.
  • Year by year, Retained Earnings stood at -$6.6 million in 2021, then tumbled by 2403.88% to -$165.3 million in 2022, then tumbled by 94.51% to -$321.5 million in 2023, then dropped by 11.24% to -$357.7 million in 2024, then rose by 6.36% to -$334.9 million in 2025.
  • Business Quant data shows Retained Earnings for BVS at -$334.9 million in Q4 2025, -$1.8 million in Q3 2025, and -$774000.0 in Q2 2025.